Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) Net Margin (2016 - 2025)

Historic Net Margin for Ani Pharmaceuticals (ANIP) over the last 15 years, with Q3 2025 value amounting to 11.53%.

  • Ani Pharmaceuticals' Net Margin rose 281000.0% to 11.53% in Q3 2025 from the same period last year, while for Sep 2025 it was 4.72%, marking a year-over-year increase of 62900.0%. This contributed to the annual value of 3.28% for FY2024, which is 68000.0% down from last year.
  • Latest data reveals that Ani Pharmaceuticals reported Net Margin of 11.53% as of Q3 2025, which was up 281000.0% from 3.85% recorded in Q2 2025.
  • Ani Pharmaceuticals' Net Margin's 5-year high stood at 12.95% during Q1 2024, with a 5-year trough of 39.93% in Q4 2021.
  • Its 5-year average for Net Margin is 6.28%, with a median of 1.95% in 2024.
  • Its Net Margin has fluctuated over the past 5 years, first plummeted by -336100bps in 2021, then surged by 349900bps in 2022.
  • Ani Pharmaceuticals' Net Margin (Quarter) stood at 39.93% in 2021, then skyrocketed by 88bps to 4.93% in 2022, then skyrocketed by 112bps to 0.57% in 2023, then crashed by -1085bps to 5.61% in 2024, then soared by 306bps to 11.53% in 2025.
  • Its last three reported values are 11.53% in Q3 2025, 3.85% for Q2 2025, and 7.75% during Q1 2025.